Holding
Eli Lilly and CompanyLLY
Tenth-place with 1,027% return (10.27x), driven by blockbuster diabetes/obesity drugs and 43% YoY revenue growth. Receives minimum 2% allocation as the only non-tech holding, providing modest sector diversification at the tail.
weight · 1.82%·sector · Healthcare